Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 4/2019

01-12-2019 | Candidiasis | Advances in Diagnosis of Invasive Fungal Infections (O Morrissey, Section Editor)

Update on the Diagnosis of Candidemia and Invasive Candidiasis

Authors: María F. Gonzalez-Lara, Luis Ostrosky-Zeichner

Published in: Current Fungal Infection Reports | Issue 4/2019

Login to get access

Abstract

Purpose of Review

This review summarizes the fungal diagnostic tests and clinical prediction rules available for use in patients at risk for developing invasive candidiasis (IC). The advantages and limitations of each method is described based on available literature.

Recent Findings

Available studies show elevated sensitivity and specificity of novel diagnostic tests such as T2Candida and fungal sequencing. They still remain to be incorporated into routine clinical practice.

Summary

The use B-D glucan, a major fungal wall component, is a sensitive tool to diagnose IC when consecutive positive results are found. Consecutively negative results allow discontinuation of empirical antifungal therapy, contributing to stewardship programs. T2Candida combines PCR and magnetic resonance to identify IC that is culture negative and monitor post-treatment candidemia clearance. Prediction rules using clinical risk factors for IC allows identification of patients likely to benefit from prophylaxis or early treatment.
Literature
1.
2.
Magill SS, O’Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, et al. Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med. 2018;379(18):1732–44.PubMedPubMedCentral
3.
Vincent J, Rello J, Marshall J, Silva E, Anzueto A, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9.PubMed
4.
5.
Cleveland AA, Harrison LH, Farley MM, Hollick R, Stein B, Chiller TM, et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One. 2015;10(3):2008–13.
6.
7.
Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133–63.PubMedPubMedCentral
8.
•• Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug-resistant candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64(2):134–40 Illustrative review on the emergence of Candida auris. PubMed
9.
Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43(1):25–31.PubMed
10.
Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obteinaed: a potential risk factor for mortality. Antimicrob Agents Chemother. 2005;49(9):3640–5.PubMedPubMedCentral
11.
•• Clancy CJ, Nguyen MH. Diagnosing invasive candidiasis. J Clin Microbiol. 2018;56(5):1–9 Recent, illustrative review article on invasive candidiasis diagnosis.
12.
13.
Pfeiffer CD, Samsa GP, Schell WA, Reller LB, Perfect JR, Alexander BD. Quantitation of candida CFU in initial positive blood cultures. J Clin Microbiol. 2011;49(8):2879–83.PubMedPubMedCentral
14.
Schell WA, Johnson MD, Alexander BD, Perfect JR, Smith PB, Benjamin DK, et al. Evaluation of a digital microfluidic real-time PCR platform to detect DNA of Candida albicans in blood. Eur J Clin Microbiol Infect Dis. 2012;31(9):2237–45.PubMedPubMedCentral
15.
Bille J, Stockman L, Roberts GD, Horstmeier CD, Ilstrup DM. Evaluation of a lysis-centrifugation system for recovery of yeasts and filamentous fungi from blood. J Clin Microbiol. 1983;18(3):469–71.PubMedPubMedCentral
16.
17.
Jaulhac B, Waller J, Candolfi E, Al MET, Icrobiol JCLINM. Comparison of mycosis IC/F and Plus Aerobic/F media for diagnosis of fungemia by the Bactec 9240 system. J Clin Microbiol. 2004;42(2):773–7.PubMedPubMedCentral
18.
Clancy CJ, Nguyen MH. Finding the missing 50% of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56(9):1284–92.PubMed
19.
Lockhart SR, Jackson BR, Vallabhaneni S, Ostrosky-Zeichner L, Pappas PG, Chiller T. Thinking beyond the common Candida species: need for species-level identification of Candida due to the emergence of multidrug-resistant Candida auris. J Clin Microbiol. 2017;55(12):3324–7.PubMedPubMedCentral
20.
21.
Theel ES, Doern CD. β-D-Glucan testing is important for diagnosis of invasive fungal infections. J Clin Microbiol. 2013;51(11):3478–83.PubMedPubMedCentral
22.
•• Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52(6):750–70 Relevant meta-analysis on the use and diagnostic yield of Beta-D-glucan. PubMed
23.
Onishi A, Sugiyama D, Kogata Y, Saegusa J, Sugimoto T, Kawano S, et al. Diagnostic accuracy of serum 1,3-β-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50(1):7–15.PubMedPubMedCentral
24.
He S, Hang JP, Zhang L, Wang F, Zhang DC, Gong FH. A systematic review and meta-analysis of diagnostic accuracy of serum 1,3-β-d-glucan for invasive fungal infection: focus on cutoff levels. J Microbiol Immunol Infect. 2015;48(4):351–61.PubMed
25.
Hanson KE, Pfeiffer CD, Lease ED, Balch AH, Zaas AK, Perfect JR, et al. Β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One. 2012;7(8):1–8.
26.
Ellis M, Al-Ramadi B, Finkelman M, Hedstrom U, Kristensen J, Ali-Zadeh H, et al. Assessment of the clinical utility of serial β-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol. 2008;57(3):287–95.PubMed
27.
Fortún J, Meije Y, Buitrago MJ, Gago S, Bernal-Martinez L, Pemán J, et al. Clinical validation of a multiplex real-time PCR assay for detection of invasive candidiasis in intensive care unit patients. J Antimicrob Chemother. 2014;69(11):3134–41.PubMed
28.
Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, et al. Performance of candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54(9):1240–8.PubMed
29.
Tissot F, Lamoth F, Hauser PM, Orasch C, Flückiger U, Siegemund M, et al. Β-Glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med. 2013;188(9):1100–9.PubMed
30.
Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55(4):521–6.PubMed
31.
Sims CR, Jaijakul S, Mohr J, Rodriguez J, Finkelman M, Ostrosky-Zeichner L. Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasis. J Clin Microbiol. 2012;50(6):2104–6.PubMedPubMedCentral
32.
• Nucci M, Nouér SA, Esteves P, Guimarães T, Breda G, de Miranda BG, et al. Discontinuation of empirical antifungal therapy in ICU patients using 1,3-β-d-glucan. J Antimicrob Chemother. 2016;71(9):2628–33 A study on the safety of discontinuating empirical antifungal therapy on critically ill patients with consecutive negative B-D glucan test. PubMed
33.
Posteraro B, Tumbarello M, De Pascale G, Liberto E, Vallecoccia MS, De Carolis E, et al. (1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. J Antimicrob Chemother. 2016;71(8):2262–9.PubMed
34.
Neely LA, Audeh M, Phung NA, Min M, Suchocki A, Plourde D, et al. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med. 2013;5(182):1–8.
35.
Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015;60(6):892–9.PubMed
36.
Clancy CJ, Pappas PG, Vazquez J, Judson MA, Kontoyiannis DP, Thompson GR, et al. Detecting infections rapidly and easily for candidemia trial, part 2 (DIRECT2): a prospective, multicenter study of the T2Candida panel. Clin Infect Dis. 2018;66(11):1678–86.PubMed
37.
Mylonakis E, Zacharioudakis IM, Clancy CJ, Hong Nguyen M, Pappas PG. Efficacy of T2 magnetic resonance assay in monitoring candidemia after initiation of antifungal therapy: the serial therapeutic and antifungal monitoring protocol (STAMP) trial. J Clin Microbiol. 2018;56(4):1–9.
38.
Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49(2):665–70.PubMedPubMedCentral
39.
León C, Ruiz-Santana S, Saavedra P, Castro C, Loza A, Zakariya I, et al. Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. Crit Care. 2016;20(1):1–14.
40.
León C, Ruiz-Santana S, Saavedra P, Galván B, Blanco A, Castro C, et al. Usefulness of the “candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37(5):1624–33.PubMed
41.
Lau AF, Kabir M, Chen SCA, Playford EG, Marriott DJ, Jones M, et al. Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol. J Clin Microbiol. 2015;53(4):1324–30.PubMedPubMedCentral
42.
Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220(6):751–8.PubMedPubMedCentral
43.
• Hermsen ED, Zapapas MK, Maiefski M, Rupp ME, Freifeld AG, Kalil AC. Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study. Crit Care. 2011;15(4):R198 Available from: http://​ccforum.​com/​content/​15/​4/​R198. Illustrative case-control study that evaluated the sensitivity and specificity of each prediction rule to rule out invasive candidiasis. PubMedPubMedCentral
44.
Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol. 2005;43(3):235–43.PubMed
45.
Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C, et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2011;54(1):46–51.PubMed
46.
Ostrosky-Zeichner L. Clinical prediction rules for invasive candidiasis in the ICU: ready for prime time? Crit Care. 2011;15(5):9–10.
47.
Moncada PA, Budvytiene I, Ho DY, Deresinski SC, Montoya JG, Banaei N. Utility of DNA sequencing for direct identification of invasive fungi from fresh and formalin-fixed specimens. Am J Clin Pathol. 2013;140(2):203–8.PubMed
48.
Lau A, Chen S, Sorrell T, Carter D, Malik R, Martin P, et al. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J Clin Microbiol. 2007;45(2):380–5.PubMed
49.
•• Gomez CA, Budvytiene I, Zemek AJ, Banaei N. Performance of targeted fungal sequencing for culture-independent diagnosis of invasive fungal disease. Clin Infect Dis. 2017;65(12):2035–41 Illustrative study that showed elevated sensitivity and specificity of performing targeted panfungal amplification followed by sequencing from tissue and sterile body fluids. PubMed
50.
51.
Halliday CL, Kidd SE, Sorrell TC, Chen SCA. Molecular diagnostic methods for invasive fungal disease: the horizon draws nearer? Pathology. 2015;47(3):257–69.PubMed
Metadata
Title
Update on the Diagnosis of Candidemia and Invasive Candidiasis
Authors
María F. Gonzalez-Lara
Luis Ostrosky-Zeichner
Publication date
01-12-2019
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 4/2019
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-019-00367-1

Other articles of this Issue 4/2019

Current Fungal Infection Reports 4/2019 Go to the issue

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz and M Pereira, Section Editors)

Adult Tinea Capitis: a Clinical Entity in Increasing Frequency

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz and M Pereira, Section Editors)

Update of Vulvovaginal Candidiasis in Pregnant and Non-pregnant Patients

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz and M Pereira, Section Editors)

Chromoblastomycosis in Solid Organ Transplant Recipients

Pediatric Fungal Infections (D Corzo-Leon, Section Editor)

From Culture to Fungal Biomarkers: the Diagnostic Route of Fungal Infections in Children with Primary Immunodeficiencies

Current Management of Fungal Infections (S Jacobs, Section Editor)

Updates on the Treatment of Non-Aspergillus Hyaline Mold Infections

Epidemiology of Fungal Infections (T Chiller and J Baddley, Section Editors)

Genetic Variation and Fungal Infection Risk: State of the Art
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits